Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Supernus Pharmaceuticals, Inc.

Market Cap 2.58B 2.25B 2.08B 1.95B 3.64B 243B 3.67B 24.66B 9.56B 120B 9.67B 9.46B 415B P/E 2026 *
102x
P/E 2027 * 31.3x
Enterprise Value 2.58B 2.25B 2.08B 1.95B 3.64B 243B 3.67B 24.66B 9.56B 120B 9.67B 9.46B 415B EV / Sales 2026 *
2.97x
EV / Sales 2027 * 2.53x
Free-Float
95.54%
Yield 2026 *
-
Yield 2027 * -
1 day+1.84%
1 week-2.57%
Current month-3.90%
1 month-8.17%
3 months-9.96%
6 months-9.94%
Current year-10.70%
1 week 42.45
Extreme 42.45
44.58
1 month 42.45
Extreme 42.45
49.83
Current year 42.45
Extreme 42.45
59.68
1 year 30.83
Extreme 30.83
59.68
3 years 21.99
Extreme 21.99
59.68
5 years 21.99
Extreme 21.99
59.68
10 years 13.12
Extreme 13.12
61.25
Manager TitleAgeSince
Chief Executive Officer 64 2005-12-21
Director of Finance/CFO 67 2021-08-22
Compliance Officer 63 2011-12-31
Director TitleAgeSince
Director/Board Member 64 2005-12-21
Chairman 80 2016-08-09
Director/Board Member 80 2010-11-15
Date Insider Type Main position Quantity % Market Cap.
03-15Fiscal year

Chief Technology Officer

321,750 0.5738%
03-12Others

Founder

60,000 0.1070%
03-11Sell

Director

5,369 0.0096%
Change 5-day change 1-year change 3-year change Capi.($)
+1.84%-2.57%+34.65%+31.42% 2.58B
-1.36%-5.71%+43.61%+4.16% 281B
-0.11%-1.85%+21.15%-20.06% 66.39B
-0.03%-3.08%+28.97%+95.97% 8.13B
+1.30%+4.49%+1.87%-8.18% 8.15B
-1.92%-1.69%-4.40%+1.40% 4.52B
-2.69%-0.39%-26.62%+36.36% 3.8B
+8.33%+4.13%-2.52%+13.60% 3.42B
-1.01%+0.39%+2.10%-27.74% 1.93B
-2.03%-3.98%-22.50%-28.01% 1.63B
Average +0.23%-2.35%+7.63%+9.89% 38.18B
Weighted average by Cap. -0.97%-4.62%+36.27%+1.90%

Financials

2026 *2027 *
Net sales 867M 756M 699M 655M 1.23B 81.79B 1.24B 8.3B 3.22B 40.27B 3.26B 3.19B 140B 1.02B 889M 822M 771M 1.44B 96.18B 1.45B 9.76B 3.78B 47.35B 3.83B 3.75B 164B
Net income 25.2M 21.97M 20.32M 19.04M 35.65M 2.38B 35.94M 241M 93.48M 1.17B 94.58M 92.55M 4.06B 82.76M 72.17M 66.74M 62.55M 117M 7.81B 118M 792M 307M 3.84B 311M 304M 13.35B
Net Debt - -
Logo Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's Disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The Company is developing a range of CNS product candidates including new potential treatments for epilepsy, depression, ADHD, and other CNS disorders. Its products marketed in the United States include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC, ONAPGOTM (formerly known as SPN-830), and ZURZUVAE. Qelbree (viloxazine extended-release capsules) is a non-stimulant product indicated for the treatment of ADHD in adults and pediatric patients 6 years and older.
Employees
778
Date Price Change Volume
26-06-18 44.38 $ +1.84% 1,096,029
26-06-17 43.58 $ 0.00% 563,031
26-06-16 43.58 $ -0.64% 720,139
26-06-15 43.86 $ -1.24% 902,284
26-06-12 44.41 $ -2.50% 825,356
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
44.38USD
Average target price
62.83USD
Spread / Average Target
+41.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SUPN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!